4.7 Article

Mild, calcium catalysed Beckmann rearrangements

期刊

CHEMICAL COMMUNICATIONS
卷 54, 期 6, 页码 654-657

出版社

ROYAL SOC CHEMISTRY
DOI: 10.1039/c7cc09491d

关键词

-

资金

  1. AbbVie [1097737]
  2. Bayer [1097737]
  3. Boehringer Ingelheim [1097737]
  4. Canada Foundation for Innovation [1097737]
  5. Canadian Institutes for Health Research [1097737]
  6. Genome Canada [1097737]
  7. GlaxoSmithKline [1097737]
  8. Janssen [1097737]
  9. Lilly Canada [1097737]
  10. Novartis Research Foundation [1097737]
  11. Ontario Ministry of Economic Development and Innovation [1097737]
  12. Pfizer [1097737]
  13. Takeda [1097737]
  14. Wellcome Trust [1097737, 092809/Z/10/Z]
  15. MMU

向作者/读者索取更多资源

A mild calcium catalysed Beckmann rearrangement has been realised, which forgoes the more traditional harsh reactions conditions associated with the transformation. The catalyst system is shown to be tolerant towards a wide variety of functional groups relevant to natural product synthesis and medicinal chemistry and the synthetic utility of the reaction has also been investigated. A preliminary mechanistic investigation was performed to understand the nature of the incoming nucleophile and a possible reaction pathway is described.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据